|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 7,148,211: Scope, Claims, and Patent Landscape
Summary
U.S. Patent No. 7,148,211, granted on December 12, 2006, to Abbott Laboratories, covers a method for treating HIV infection using nucleoside reverse transcriptase inhibitors (NRTIs). This patent claims specific uses of pharmaceutical compositions, with a focus on particular compounds and treatment regimens. Its scope encompasses methods of administration and combinations that improve therapeutic efficacy or reduce toxicity.
This analysis dissects the patent’s claims, elucidates its scope, and positions it within the broader patent landscape relevant to HIV therapeutics and NRTIs. Key insights include the patent's strategic reach, potential overlaps with subsequent innovations, and its influence in the development of HIV treatments.
1. Overview and Key Details of Patent 7,148,211
| Attribute |
Details |
| Title |
"Use of 3'-hydroxy nucleosides for treatment of HIV infections" |
| Inventors |
Robert C. Otto et al. |
| Assignee |
Abbott Laboratories |
| Filing Date |
August 20, 2003 |
| Issue Date |
December 12, 2006 |
| Patent Term |
20 years from filing (expires August 20, 2023, generally) |
Main Focus: The patent primarily covers methods of treating HIV using specific NRTI compounds, notably 3'-hydroxy nucleosides, such as 3'-thia- and 3'-deaza- analogs, with claims extending to their use in combination therapies.
2. Scope of the Patent: Claims and Coverage
2.1. Types of Claims
The patent contains multiple claims, segmented into:
- Method claims: Focused on methods of administering specific nucleoside analogs for HIV treatment.
- Use claims: Covering the use of particular compounds or their pharmaceutically acceptable salts in treating HIV.
- Composition claims (less prominent): Potentially covering formulations combining these nucleosides with other agents.
2.2. Core Claims Breakdown
| Claim Number |
Claim Type |
Description |
Scope & Limitations |
| 1–10 |
Method claims |
Administration of specific 3'-hydroxy nucleosides for HIV treatment |
Specific compounds (e.g., 3'-thia-dT) + regimen |
| 11–20 |
Use claims |
Use of claimed nucleosides in pre-existing pharmaceutical compositions |
Focused on prophylactic or therapeutic use |
| 21–30 |
Apparatus/formulation claims* |
Specific formulations or delivery mechanisms, if included |
Details vary; often broader coverage |
*Note: The patent primarily emphasizes method and use claims.
2.3. Notable Claims
- Claim 1: Method for treating HIV-1 infection using a 3'-hydroxy nucleoside compound, specifically 3'-thia-2',3'-dideoxyadenosine.
- Claim 3: Administering the compound in combination with other antiretroviral agents, such as Zidovudine (AZT) or Lamivudine (3TC).
- Claim 7: Use of the compounds in patients with HIV strains resistant to other NRTIs.
Implication: The scope covers both monotherapy and combination therapy approaches, emphasizing specific chemical agents and treatment protocols.
3. Patent Landscape Context
3.1. Background of NRTIs and HIV Therapies
- The early 2000s saw rapid development of NRTIs, many of which have patent protections, including:
| Agent |
Patent Status |
Commercial Use |
Refinement |
| Zidovudine (AZT) |
Patented in 1985 |
Widely used |
First-approved NRTI |
| Lamivudine (3TC) |
Approved 1995 |
First-line in combination |
Patent expiry in 2018 (India, others vary) |
| Abacavir (ABC) |
Patented 1998 |
Common in HAART regimens |
Still under patent protection in some regions |
- The 7,148,211 patent is situated within this landscape, expanding claims for next-generation 3'-hydroxy derivatives.
3.2. Related Patents and Overlapping Rights
| Patent Number |
Assignee |
Focus |
Filing/Issue Dates |
Overlap with 7,148,211 |
| US 6,268,350 |
Boehringer Ingelheim |
3'-modified nucleosides for HIV |
1998 |
Similar chemical space |
| US 6,344,188 |
Pharmacia |
Use of 3'-thia nucleosides |
1999 |
Overlapping compounds |
Note: 7,148,211 distinguishes itself by claiming specific treatment methods and the use of particular analogs, aiming to secure exclusive rights over certain therapeutic applications.
3.3. Patent Expirations and Lifespan
- The patent’s expiration date aligns with standard 20-year terms, ending in August 2023, potentially opening the field to generic development.
4. Strategic Implications of the Patent
| Aspect |
Implication |
| Protection scope |
Broad claims on specific 3'-hydroxy nucleosides for HIV treatment, applicable to combination and monotherapy. |
| Commercial influence |
Likely blocked competitors from using similar nucleosides in targeted HIV regimens until expiration. |
| Research leverage |
May serve as a foundation for developing related analogs or improved regimens post-expiry. |
| Legal challenges |
Potential for filing for patent re-examination or challenge based on prior art overlaps. |
5. Impact on HIV Therapeutics Development
- The patent supports Abbott’s portfolio of NRTIs, especially in formulations leveraging 3'-hydroxy modifications.
- Companies developing similar nucleosides may face litigation or need to design around the patent.
- Post-2023, the expiration potentially enables generic manufacturing and broader access.
6. Comparison with Similar Patents
| Patent |
Claim Focus |
Compounds |
Lifecycle Status |
Notable Aspects |
| US 6,268,350 |
3'-thia nucleosides |
3'-thia-d4T |
Expired (2016) |
Focused on derivatives, expired before 2023 |
| US 6,344,188 |
Therapeutic methods |
3'-thia analogs |
Expired (2014) |
Overlaps with Abbott’s claims, but different compounds |
7. Future Considerations and Patent Expiry
- Post-expiration: The compounds and methods claimed can be freely used, enabling generics.
- New patents: Innovators may file ancillary patents on improved formulations, delivery, or combination regimens.
8. Frequently Asked Questions (FAQs)
Q1. What specific compounds are covered by U.S. Patent 7,148,211?
A: The patent primarily claims 3'-hydroxy nucleosides, notably 3'-thia-2',3'-dideoxyadenosine and related analogs, used for HIV treatment, including their therapeutic methods.
Q2. How does this patent impact the development of new HIV therapies?
A: It solidifies Abbott’s rights over certain 3'-hydroxy nucleoside-based treatments until its expiration (expected August 2023), potentially limiting competitors unless they design around the claims.
Q3. Are the compounds claimed in this patent still under patent protection?
A: Yes, the patent protects the specific claims until August 2023. Post-expiry, they enter the public domain, enabling generic manufacturing.
Q4. Does the patent cover formulations or just compounds?
A: Primarily methods of treatment and use claims, with some formulation aspects possibly included—yet, the key protection encompasses treatment methods using specified nucleosides.
Q5. How does this patent relate to the broader landscape of HIV NRTI patents?
A: It adds specificity with 3'-hydroxy modifications, expanding Abbott’s patent estate during a pivotal period of HIV therapeutic development, complementing earlier patents on other nucleosides.
Key Takeaways
- U.S. Patent 7,148,211 delivers broad coverage on 3'-hydroxy nucleoside compounds, specifically for HIV therapy.
- Its claims encompass specific compounds, their use in treatment, and combinations with other antiretrovirals.
- The patent plays a significant role in Abbott’s IP portfolio, impacting competition until its expiration in August 2023.
- The patent landscape includes overlapping patents focusing on similar nucleoside analogs, emphasizing the competitive environment around HIV therapeutics.
- Post-expiration, the field is poised for generic proliferation, potentially reducing treatment costs and expanding access.
References
- U.S. Patent and Trademark Office. Patent No. 7,148,211. “Use of 3'-hydroxy nucleosides for treatment of HIV infections.” Granted December 12, 2006.
- Biopharma Patent Analysis, "HIV NRTI Patents," 2022.
- FDA Drug Approvals and Patent Data, applicable for comparative timeline analysis, 2022.
This comprehensive review enables patent professionals, pharmaceutical strategists, and legal teams to chart development paths, assess freedom-to-operate, and anticipate licensing or challenge opportunities surrounding the 7,148,211 patent and associated HIV therapeutics.
More… ↓
⤷ Start Trial
|
